Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBOW-Asia: Ramucirumab + Paclitaxel in Advanced Gastric/GEJ Cancer
NCT02898077Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2017
- Primary completion
- Jun 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of ramucirumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Eli Lilly and Company. Started Mar 2017; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02898077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02898077.